Keyphrases
ANCA-associated Vasculitis
20%
Anti-Ro
10%
Antineutrophil Cytoplasmic Antibody
10%
Autoimmune Syndrome
10%
Autoimmunity
20%
Biological Agents
12%
Blood Concentration
20%
Cardiac Disease
20%
Cardiovascular Disease
20%
Cognitive Dysfunction
20%
Cognitive Function
16%
Cognitive Symptoms
12%
Complement Split Products
20%
Complementary and
20%
Complementary Medicine
20%
Complete Resolution
10%
Cutaneous Vasculitis
10%
Daily Life
20%
Dermatomyositis
10%
Disease Activity
13%
Disease Control
20%
Disease-modifying Antirheumatic Drugs (DMARDs)
34%
Drug-induced Diseases
10%
Early Rheumatoid Arthritis
20%
Ezetimibe
20%
High Titer
10%
IC3b
20%
Lupus
20%
Montreal Cognitive Assessment (MoCA)
12%
Panacea
20%
Patient Response
15%
Pharmacogenetics
35%
Placebo
20%
Rheumatoid Arthritis
100%
Rheumatoid Arthritis Treatment
8%
Rheumatologic Diseases
20%
Rheumatology
20%
Serologic Findings
10%
Simvastatin
20%
SLE Disease Activity Index (SLEDAI)
20%
Statin Use
10%
Statins
20%
Symptom Resolution
10%
Systemic Lupus Erythematosus
48%
Temporal Course
10%
Tight
20%
Treat-to-target
10%
Vasculitis
10%
Vitamin D
20%
Vitamin D Deficiency
10%
Medicine and Dentistry
Adaptive Immunity
5%
Atherosclerosis
5%
Autoimmunity
20%
Biological Product
11%
Cardiovascular Disease
22%
Cardiovascular Risk
5%
Cardiovascular System
5%
Combination Therapy
25%
Complementary and Alternative Medicine
20%
Cutaneous Vasculitis
10%
Dermatomyositis
10%
Disease Activity
30%
Disease Modifying Antirheumatic Drug
17%
Diseases
45%
Drug Induced Disease
10%
Ezetimibe/Simvastatin
20%
Heart Disease
20%
Hypovitaminosis D
10%
Inflammatory Arthritis
100%
Innate Immunity
5%
Medicine
20%
Neutrophil Cytoplasmic Antibody
10%
Oral Submucous Fibrosis
5%
Pharmacogenetics
12%
Placebo
20%
Prednisone
5%
Rheumatic Disease
10%
Rheumatoid Arthritis
100%
Rheumatology
21%
Ro Antibody
10%
Statin
20%
Systemic Lupus Erythematosus
30%
Vasculitis
20%
Vitamin D
20%
Vitamin D Deficiency
10%
Pharmacology, Toxicology and Pharmaceutical Science
Biological Product
16%
Cardiovascular Risk
5%
Cognitive Defect
20%
Combination Therapy
5%
Disease Activity
10%
Disease Modifying Antirheumatic Drug
29%
Diseases
42%
Heart Disease
20%
Hypovitaminosis D
10%
Inflammatory Arthritis
100%
Mouth Disease
5%
Pharmacogenetics
32%
Pharmacotherapy
6%
Placebo
20%
Remission
5%
Rheumatoid Arthritis
100%
Systemic Lupus Erythematosus
20%
Vitamin D
20%
Vitamin D Deficiency
10%
